The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 299, Issue 2, 2010, Pages

  Rosanò, Laura ^a   Spinella, Francesca ^a   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Endothelin A receptor; Ovarian cancer; Targeted therapy

Indexed keywords

ATRASENTAN; CISPLATIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PACLITAXEL;

CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; METASTASIS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENDOTHELIN-1; FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTOR, ENDOTHELIN A; SIGNAL TRANSDUCTION;

EID: 77955489086     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00304.2010     Document Type: Review

References (79)

1. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N. Molecular pathways regulating EGF-induced epitheliomesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290: C1532-C1542, 2006.
2. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, Roskelley CD. E-cadherin induces mesenchymalto-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96: 6249-6254, 1999.
3. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 9: 378-383, 1998.
4. Bagnato A, Rosanò L. The endothelin axis in cancer. Int J Biochem Cell Biol 40: 1443-1451, 2008.
5. Bagnato A, Rosanò L. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cells Tissues Organs 185: 85-94, 2007.
6. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 14: 44-50, 2003.
7. Bagnato A, Spinella F, Rosanò L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 12: 761-772, 2005.
8. Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86: 473-484, 2008.
9. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 59: 720-727, 1999.
10. Bagnato A, Tecce R, Di Castro V, Catt KJ. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res 57: 1306-1311, 1997.
11. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1: 1059-1066, 1995.
12. Barki-Harrington L, Rockman HA. Beta-arrestins: multifunctional cellular mediators. Physiology 23: 17-22, 2008.
13. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428, 2009.
14. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 14: 385-399, 1993.
15. Burkhardt M, Barton M, Shaw SG. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade. J Hypertens 18: 273-279, 2000.
16. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
17. Clasper S, Royston D, Baban D, Cao Y, Ewers S, Butz S, Vestweber D, Jackson DG. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res 68: 7293-7303, 2008.
18. Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A. β-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. Can J Physiol Pharmacol In press.
19. Defea K. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 153 Suppl 1: S298-S309, 2008.
20. Del Bufalo D, Di Castro V, Biroccio A, Salani D, Rosanò L, Spinella F, Bagnato A. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 103 Suppl 48: 302S-305S, 2002.
21. Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosanò L, Trisciuoglio D, Spinella F, Bagnato A. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 61: 524-532, 2002.
22. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903, 2002. (Pubitemid 34224579)
23. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23: 8065-8077, 2004.
24. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 35: 663-669, 2004. (Pubitemid 38881075)
25. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13: 1205-1211, 2002. (Pubitemid 34960128)
26. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
27. Fosslien E. Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 31: 325-348, 2001.
28. Gavert N, and Ben-Ze'ev A. β-Catenin signaling in biological control and cancer. J Cell Biochem 102: 820-828, 2007.
29. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 97: 779-784, 2003.
30. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, DuBois RN. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63: 906-911, 2003.
31. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 5: 51-63, 2005.
32. Helleman J, Smid M, Jansen MP, van der Burg ME, Berns EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 117: 170-176, 2010.
33. Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I. Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 35: 1469-1476, 2004.
34. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310, 2005. (Pubitemid 41262961)
35. Kajiyama H, Shibata K, Terauchi M, Morita T, Ino K, Mizutani S, Kikkawa F. Neutral endopeptidase 2411/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res 11: 1798-1808, 2005.
36. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, Kikkawa F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283, 2007.
37. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115: 455-65, 2002.
38. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci 25: 219-224, 2004.
39. Meidan R, Nitzan L. The ovarian endothelin network: an evolving story. Trends Endocrinol Metab 18: 379-385, 2007.
40. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer 5: 355-366, 2005.
41. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116, 2003.
42. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428, 2007.
43. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
44. Rayhman O, Klipper E, Muller L, Davidson B, Reich R, Meidan R. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res 68: 9265-78, 2008.
45. Rosanò L, Bagnato A. Convergent pathways link the endothelin A receptor to the beta-catenin: the β-arrestin connection. Cell Cycle 8: 1462-1463, 2009.
46. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106: 2806-2811, 2009.
47. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A. Combination therapy of zibotentan with cisplatinum and taxol is an effective regimen for epithelial ovarian cancer. Can J Physiol Pharmacol In press.
48. Rosanò L, Di Castro V, Spinella F, Decandia S, Natali PG, Bagnato A. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) 231: 1132-1135, 2006.
49. Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 6: 2003-2011, 2007.
50. Rosanò L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 67: 6351-6359, 2007.
51. Rosanò L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 103 Suppl 48: 306S-309S, 2002.
52. Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood) 231: 1128-1131, 2006.
53. Rosanò L, Spinella F, Di Castro V, Dedhar S, Nicotra MR, Natali PG, Bagnato A. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther 5: 833-842, 2006.
54. Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A. Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. J Cardiovasc Pharmacol 44 Suppl 1: S132-S135, 2004.
55. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, Bagnato A. Endothelin-1 promotes epithelialto- mesenchymal transition in human ovarian cancer cells. Cancer Res 65: 11649-11657, 2005.
56. Rosanò L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res 63: 2447-2453, 2003.
57. Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61: 8340-8346, 2001.
58. Rubin SA, Levin ER. Clinical review 53: The endocrinology of vasoactive peptides: synthesis to function. J Clin Endocrinol Metab 78: 6-10, 1994.
59. Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, Natali PG, Bagnato A. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157: 1537-1547, 2000.
60. Salani D, Rosanò L, Di Castro V, Spinella F, Venuti A, Padley RJ, Nicotra MR, Natali PG, Bagnato A. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond) 103 Suppl 48: 318S-321S, 2002.
61. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, Bagnato A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 157: 1703-1711, 2000.
62. Spinella F, Caprara V, Garrafa E, Di Castro V, Rosanò L, Natali PG, Bagnato A. Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can J Physiol Pharmacol In press.
63. Spinella F, Garrafa E, Di Castro V, Rosanò L, Nicotra MR, Caruso A, Natali PG, Bagnato A. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 69: 2669-2676, 2009.
64. Spinella F, Rosanò L, Decandia S, Di Castro V, Albini A, Elia G, Natali PG, Bagnato A. Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target. Exp Biol Med (Maywood) 231: 1123-1127, 2006.
65. Spinella F, Rosanò L, Di Castro V, Decandia S, Albini A, Nicotra MR, Natali PG, Bagnato A. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther 5: 1483-1492, 2006.
66. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 277: 27850-27855, 2002.
67. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin-1- induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 279: 46700-46705, 2004.
68. Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 278: 41294-41301, 2003.
69. Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res 10: 4670-4679, 2004.
70. Spinella F, Rosanò L, Elia G, Di Castro V, Natali PG, Bagnato A. Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J Cardiovasc Pharmacol 44 Suppl 1: S140-S143, 2004.
71. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
72. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716, 1998.
73. Umhauer S, Ruch RJ, Fanning J. Gap junctional intercellular communication and connexin 43 expression in ovarian carcinoma. Am J Obstet Gynecol 182: 999-1000, 2000.
74. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 60: 5310-5317, 2000.
75. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 265: 14150-14155, 1990.
76. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven- transmembrane receptors. Trends Pharmacol Sci 28: 416-22, 2007.
77. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, Greb RR, Bocker W, Kiesel L. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9: 4125-4131, 2003.
78. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78: 473-485, 1994.
79. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.